Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial
Jiwon Lee, Kaylyssa Philip, Hance Clarke, Cheryl Pritlove, Joel Katz, Paul Ritvo, Akash Goel, Muhammad Ishrat Husain, Duminda N. Wijeysundera, Karim S. Ladha
Canadian Journal of Pain November 8, 2024 DOI: 10.1080/24740527.2024.2406285 via OpenAlex
Summary
AI-generated from the abstractA proposed clinical trial design for psilocybin as a treatment for neuropathic pain, called the PEACE-PAIN trial, is supported by patient survey responses but could be improved by adding detailed discussions of the existing evidence on efficacy, safety, tolerability, and management of adverse effects. The finding that individuals with prior psychedelic use are interested in participating has important implications for the trial's inclusion and exclusion criteria.
Study at a glance
| Characteristics | Clinical trial design Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Psilocybin |
| Keywords | Neuropathic pain Chronic pain Medicine Anesthesia |
| Citations | 3 |
| Key finding | The PEACE-PAIN trial design is supported by patient survey responses but may benefit from modifications, particularly regarding discussions of evidence and adverse effects, and prior psychedelic use among interested participants has methodological implications for inclusion/exclusion criteria. |
Abstract
The PEACE-PAIN trial study design is supported by patient survey responses but may benefit from modifications, namely incorporating thorough discussions of the current evidence for efficacy, safety, tolerability, and approaches to address adverse effects of psilocybin. Additionally, the interest in participation by individuals with prior psychedelic use holds important methodological implications for the inclusion/exclusion criteria of the trial.